Use of the tumor necrosis factor-blockers for Crohn's disease

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 35

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

637

HTML

5953

Figures (1-2)

255

Tables (1-38)

247

Sum=7092

Sep 21, 2012 (publication date) through Nov 5, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Guidelines For Clinical Practice

World J Gastroenterol. Sep 21, 2012; 18(35): 4823-4854
Published online Sep 21, 2012. doi: 10.3748/wjg.v18.i35.4823

Table 22 Adalimumab for fistulizing Crohn's disease induction, response and closure (%)

¹40 mg at week 0, 20 mg at week 2;

²80 mg at week 0, 40 mg at week 2;

³160 mg at week 0, 80 mg at week 2. ADA: Adalimumab; PL: Placebo; TG: Therapeutic gain.

Citation: Thomson AB, Gupta M, Freeman HJ. Use of the tumor necrosis factor-blockers for Crohn's disease. World J Gastroenterol 2012; 18(35): 4823-4854
URL: https://www.wjgnet.com/1007-9327/full/v18/i35/4823.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i35.4823